Expanding Horizons for Treatment of Early-Stage Lung Cancer
Mené sur des patients atteints d'un cancer du poumon non à petites cellules pouvant être réséqué, cet essai de phase III évalue l'efficacité, du point de vue de la survie sans événement et du taux de réponse pathologique complète, et la toxicité de l'ajout du nivolumab à une chimiothérapie néoadjuvante
Lung cancer remains the leading cause of cancer-related death worldwide.1 Even in the context of early-stage disease, survival among patients with lung cancer lags behind that among patients with other common cancers, such as colon, breast, and prostate cancer. The likelihood of 5-year survival remains modest,2 with patients having both local or regional relapse and metastatic relapse. Although surgery with curative intent remains the foundation for management of early-stage lung cancer, these data speak to the urgent need for improvements in systemic control. With the advent of targeted therapies directed against mutant oncoproteins and immune-checkpoint inhibitors to promote host antitumor .
New England Journal of Medicine , éditorial, 2021